Pandemic influenza vaccine (H1N1) (split virion, inactivated, adjuvanted, GlaxoSmithKline)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NamePandemic influenza vaccine (H1N1) (split virion, inactivated, adjuvanted, GlaxoSmithKline)
Drug Alias Name大流行流感疫苗（GlaxoSmithKline Biologicals S.A.）H1N1流感裂解灭活佐剂疫苗（GlaxoSmithKline Biologicals S.A.）ArepanrixGSK-2340274AGSK-2340272A +[7] 
ClassificationVaccines > Development/production technology > Inactivated vaccine > Split vaccineVaccines > Application > Prophylactic vaccineVaccines > Biological material > Viral vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsInfluenza, Human
Global Approved IndicationsInfluenza, Human
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2010/03/23
Country/TerritoryBelgiumGermanyEU
CombinationsNo
Global Highest StatusWithdrawn
Highest Status in ChinaN/A
Originator CompaniesGlaxosmithkline Biologicals SA
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGlaxosmithkline PlcGlaxosmithkline Biologicals SA
Active IndicationsN/A
Inactive IndicationsInfluenza, Human

Other Information

ATC CodeJ07BB02
Related LinksN/A